Compare Adaptive Biotechnologies Corp (ADPT) vs SAP SE (SAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs SAP SE — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while SAP SE trades at $157.83 (market cap $191.33B). The key difference: SAP SE is far larger — about 57.5× Adaptive Biotechnologies Corp's market cap, and SAP SE pays a 1.8% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SAP | |
|---|---|---|
Market Cap | $3.33B | $191.33B |
Sector | Health | Technology |
52-Week High | $22.37 | $311.93 |
52-Week Low | $10.24 | $148.06 |
Enterprise Value | $3.19B | $188.85B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SAP trades at $162.77, up 0.11% with recent earnings beats driving positive momentum. The stock shows strong fundamentals with 19.58% net margins and consistent revenue growth to $36.8B in 2025. Technical indicators are mixed with bearish moving averages but neutral oscillators, while analyst consensus remains bullish with a $228.50 price target representing 40% upside potential from current levels.
SAP presents a compelling investment case with robust profitability and strategic AI investments, though near-term technical weakness and competitive pressures from Oracle's AI spending create headwinds. The company's cloud transition progress and strong cash flow generation support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
